• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Henry Schein Reports Solid First-Quarter 2024 Financial Results and Updates 2024 Financial Guidance

    5/7/24 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    • First-quarter 2024 sales growth of 3.7%, GAAP diluted EPS of $0.72 and non-GAAP diluted EPS of $1.10
    • Tightens total sales growth guidance range to 8% to 10%, reflecting continued recovery from last year's cyber incident and a strong pipeline of new specialty products and software innovation
    • Affirms 2024 non-GAAP diluted EPS guidance of $5.00 to $5.16 and 2024 Adjusted EBITDA growth of more than 15%

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 30, 2024.

    "Our first-quarter financial results reflect solid earnings driven by gross margin expansion and a strong recovery from last quarter's cyber incident," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. "We continue to make good progress on executing our BOLD+1 Strategic Plan and are pleased with the contribution from our recent acquisitions."

    "We are affirming our expectations for 2024 non-GAAP diluted EPS and 2024 Adjusted EBITDA growth and tightening our expectations for 2024 total sales growth. Our projected sales growth reflects continued recovery from last year's cyber incident and a strong pipeline of new specialty products and software innovation," Mr. Bergman added.

    First-Quarter 2024 Financial Results

    • Total net sales for the quarter were $3.2 billion, an increase of 3.7% compared with the first quarter of 2023. Internal sales decreased 1.8%1 which includes:
      • an approximate 300 to 400 basis points decrease in sales from the residual impact of last year's cyber incident, and
      • a 60 basis point decrease in sales due to lower personal protective equipment (PPE) sales, primarily due to lower glove pricing.
    • First-quarter sales and internal sales growth are summarized below and detailed in Exhibit A1.

     

    Sales

    ($ Billion)

    Total

    Growth/(Decrease)1

    (%)



    Internal

    Growth/(Decrease)1

    (%)



    Global Dental

    $1.9

    0.8%

    (2.9%)

    Merchandise

    $1.5

    0.8%

    (3.7%)

    Equipment

    $0.4

    0.8%

    0.2%

    Global Medical

    $1.0

    7.3%

    (0.7%)

    Global Technology and Value-Added Services

    $0.2

    13.8%

    3.2%

     

     

     

     

    TOTAL SALES

    $3.2

    3.7%

    (1.8%)

     

    Note: items may not sum due to rounding

    • GAAP net income2 for the quarter was $93 million, or $0.72 per diluted share4, and compares with first-quarter 2023 GAAP net income of $121 million, or $0.91 per diluted share.
    • Non-GAAP net income2 for the quarter was $143 million, or $1.10 per diluted share4, and compares with first-quarter 2023 non-GAAP net income of $161 million, or $1.21 per diluted share.
    • Adjusted EBITDA3 for the quarter was $255 million, consistent with the first-quarter 2023 Adjusted EBITDA of $256 million.

    Capital Deployment

    During the first quarter of 2024, the Company repurchased approximately 1 million shares of its common stock at an average price of $75.10 per share, for a total of approximately $75 million. The impact of the share repurchases on first-quarter diluted EPS was immaterial.

    At quarter-end, Henry Schein had approximately $190 million authorized and available for future stock repurchases.

    2024 Financial Guidance

    Guidance is for current continuing operations as well as acquisitions that have closed and does not include the impact of future share repurchases, potential future acquisitions, restructuring and integration expenses, amortization expense of acquired intangible assets, contingent consideration revaluation adjustments, certain expenses directly associated with the cybersecurity incident or any potential insurance claim recovery. This guidance also assumes that foreign currency exchange rates remain generally consistent with current levels and that end markets remain consistent with current market conditions:

    • 2024 non-GAAP diluted EPS attributable to Henry Schein, Inc. is expected to be $5.00 to $5.16, unchanged from prior guidance, reflecting growth of 11% to 15% compared with 2023 non-GAAP diluted EPS of $4.50.
    • 2024 total sales growth is now expected to be approximately 8% to 10% over 2023, compared with prior guidance of 8% to 12% growth. This reflects continued recovery from last year's cyber incident and a strong pipeline of new specialty products and software innovation.
    • 2024 Adjusted EBITDA3 is expected to increase by more than 15% compared with 2023, unchanged from prior guidance.

    Adjustments to 2024 GAAP Net Income and Diluted EPS

    The Company is providing guidance for 2024 diluted EPS on a non-GAAP basis and for 2024 Adjusted EBITDA, as noted above. The Company is not providing a reconciliation of its 2024 non-GAAP guidance to its projected 2024 diluted EPS prepared on a GAAP basis, or its projected 2024 Adjusted EBITDA to net income prepared on a GAAP basis. This is because the Company is unable to provide without unreasonable effort an estimate of integration and restructuring costs related to an ongoing initiative to drive operating efficiencies, including the corresponding tax effect, that will be included in the Company's 2024 diluted EPS and net income prepared on a GAAP basis. The inability to provide this reconciliation is due to the uncertainty and inherent difficulty of predicting the occurrence, magnitude, financial impact and timing of related costs.

    Management does not believe these items are representative of the Company's underlying business performance. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

    1 See Exhibit A for details of sales growth. Internal sales growth is calculated from total net sales using constant foreign exchange rates and excludes sales from acquisitions.

    2 See Exhibit B for a reconciliation of GAAP net income and diluted EPS to non-GAAP net income and diluted EPS.

    3 See Exhibit C for a reconciliation of GAAP net income to Adjusted EBITDA.

    4 References to diluted EPS refer to diluted EPS attributable to Henry Schein, Inc.

    First-Quarter 2024 Conference Call Webcast

    The Company will hold a conference call to discuss first-quarter 2024 financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call through Henry Schein's website by visiting www.henryschein.com/IRwebcasts. In addition, a replay will be available beginning shortly after the call has ended for a period of one week.

    The Company will be posting slides that provide a summary of its first-quarter 2024 financial results on its website at https://www.henryschein.com/us-en/Corporate/investor-presentations.aspx.

    About Henry Schein, Inc.

    Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

    Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our main distribution centers.

    A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company's sales reached $12.3 billion in 2023, and have grown at a compound annual rate of approximately 11.5 percent since Henry Schein became a public company in 1995.

    For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and @HenrySchein on X.

    Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information

    In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements include EPS and Adjusted EBITDA guidance and are generally identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate," "to be," "to make" or other comparable terms. A fuller discussion of our operations, financial condition and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

    Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: our dependence on third parties for the manufacture and supply of our products; our ability to develop or acquire and maintain and protect new products (particularly technology products) and technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits, as well as significant demands on our operations, information systems, legal, regulatory, compliance, , financial and human resources functions in connection with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related to the sale of corporate brand products; security risks associated with our information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident); effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; changes in the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global and domestic macro-economic and political conditions, including inflation, deflation, recession, ongoing wars, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies, and changes to other economic indicators, international trade agreements, potential trade barriers and terrorism; geopolitical wars; failure to comply with existing and future regulatory requirements; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation; risks related to product liability, intellectual property and other claims; risks associated with customs policies or legislative import restrictions; risks associated with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or similar wide-spread public health concerns and other natural or man-made disasters; risks associated with our global operations; litigation risks; new or unanticipated litigation developments and the status of litigation matters; our dependence on our senior management, employee hiring and retention, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority.

    We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law.

    Included within the press release are non-GAAP financial measures that supplement the Company's Consolidated Statements of Income prepared under generally accepted accounting principles (GAAP). These non-GAAP financial measures adjust the Company's actual results prepared under GAAP to exclude certain items. In the schedules attached to the press release, the non-GAAP measures have been reconciled to and should be considered together with the Consolidated Statements of Income. Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. The impact of certain items that are excluded include integration and restructuring costs, and amortization of acquisition-related assets, because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate and occur on an unpredictable basis. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures.

    (TABLES TO FOLLOW)

    HENRY SCHEIN, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (in millions, except share and per share data)

    (unaudited)

     

     

     

    Three Months Ended

     

     

    March 30,

     

    April 1,

     

     

    2024

     

    2023

     

     

     

     

     

     

     

    Net sales

     

    $

    3,172

     

    $

    3,060

    Cost of sales

     

     

    2,160

     

     

    2,094

    Gross profit

     

     

    1,012

     

     

    966

    Operating expenses:

     

     

     

     

     

     

    Selling, general and administrative

     

     

    791

     

     

    717

    Depreciation and amortization

     

     

    61

     

     

    44

    Restructuring costs

     

     

    10

     

     

    30

    Operating income

     

     

    150

     

     

    175

    Other income (expense):

     

     

     

     

     

     

    Interest income

     

     

    5

     

     

    3

    Interest expense

     

     

    (30)

     

     

    (14)

    Other, net

     

     

    2

     

     

    (1)

    Income before taxes, equity in earnings of affiliates and noncontrolling interests

     

     

    127

     

     

    163

    Income taxes

     

     

    (32)

     

     

    (39)

    Equity in earnings of affiliates, net of tax

     

     

    3

     

     

    4

    Net income

     

     

    98

     

     

    128

    Less: Net income attributable to noncontrolling interests

     

     

    (5)

     

     

    (7)

    Net income attributable to Henry Schein, Inc.

     

    $

    93

     

    $

    121

     

     

     

     

     

     

     

    Earnings per share attributable to Henry Schein, Inc.:

     

     

     

     

     

     

     

     

     

     

     

     

     

    Basic

     

    $

    0.72

     

    $

    0.92

    Diluted

     

    $

    0.72

     

    $

    0.91

     

     

     

     

     

     

     

    Weighted-average common shares outstanding:

     

     

     

     

     

     

    Basic

     

     

    128,720,661

     

     

    131,365,789

    Diluted

     

     

    129,769,580

     

     

    133,039,886

    HENRY SCHEIN, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in millions, except share data)

     

     

     

    March 30,

     

    December 30,

     

     

    2024

     

    2023

     

     

    (unaudited)

     

     

     

    ASSETS

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    159

     

    $

    171

    Accounts receivable, net of allowance for credit losses of $84 and $83

     

     

    1,644

     

     

    1,863

    Inventories, net of reserves of $188 and $192

     

     

    1,686

     

     

    1,815

    Prepaid expenses and other

     

     

    589

     

     

    639

    Total current assets

     

     

    4,078

     

     

    4,488

    Property and equipment, net

     

     

    500

     

     

    498

    Operating lease right-of-use assets

     

     

    314

     

     

    325

    Goodwill

     

     

    3,835

     

     

    3,875

    Other intangibles, net

     

     

    915

     

     

    916

    Investments and other

     

     

    503

     

     

    471

    Total assets

     

    $

    10,145

     

    $

    10,573

     

     

     

     

     

     

     

    LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

    Accounts payable

     

    $

    879

     

    $

    1,020

    Bank credit lines

     

     

    264

     

     

    264

    Current maturities of long-term debt

     

     

    103

     

     

    150

    Operating lease liabilities

     

     

    75

     

     

    80

    Accrued expenses:

     

     

     

     

     

     

    Payroll and related

     

     

    245

     

     

    332

    Taxes

     

     

    143

     

     

    137

    Other

     

     

    625

     

     

    700

    Total current liabilities

     

     

    2,334

     

     

    2,683

    Long-term debt

     

     

    2,010

     

     

    1,937

    Deferred income taxes

     

     

    77

     

     

    54

    Operating lease liabilities

     

     

    266

     

     

    310

    Other liabilities

     

     

    423

     

     

    436

    Total liabilities

     

     

    5,110

     

     

    5,420

     

     

     

     

     

     

     

    Redeemable noncontrolling interests

     

     

    798

     

     

    864

    Commitments and contingencies

     

     

     

     

     

     

     

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

     

     

     

    Preferred stock, $0.01 par value, 1,000,000 shares authorized, none outstanding

     

     

    -

     

     

    -

    Common stock, $0.01 par value, 480,000,000 shares authorized, 128,480,909 outstanding on March 30, 2024 and 129,247,765 outstanding on December 30, 2023

     

     

    1

     

     

    1

    Additional paid-in capital

     

     

    -

     

     

    -

    Retained earnings

     

     

    3,838

     

     

    3,860

    Accumulated other comprehensive loss

     

     

    (239)

     

     

    (206)

    Total Henry Schein, Inc. stockholders' equity

     

     

    3,600

     

     

    3,655

    Noncontrolling interests

     

     

    637

     

     

    634

    Total stockholders' equity

     

     

    4,237

     

     

    4,289

    Total liabilities, redeemable noncontrolling interests and stockholders' equity

     

    $

    10,145

     

    $

    10,573

    HENRY SCHEIN, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in millions)

    (unaudited)

     

     

     

    Three Months Ended

     

     

    March 30,

     

    April 1,

     

     

    2024

     

    2023

     

     

     

     

     

     

     

    Cash flows from operating activities:

     

     

     

     

     

     

    Net income

     

    $

    98

     

    $

    128

    Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     

     

     

     

    Depreciation and amortization

     

     

    73

     

     

    52

    Non-cash restructuring charges

     

     

    1

     

     

    7

    Stock-based compensation expense

     

     

    8

     

     

    10

    Provision for losses on trade and other accounts receivable

     

     

    5

     

     

    1

    Provision for deferred income taxes

     

     

    2

     

     

    2

    Equity in earnings of affiliates

     

     

    (3)

     

     

    (4)

    Distributions from equity affiliates

     

     

    2

     

     

    2

    Changes in unrecognized tax benefits

     

     

    2

     

     

    1

    Other

     

     

    (6)

     

     

    (1)

    Changes in operating assets and liabilities, net of acquisitions:

     

     

     

     

     

     

    Accounts receivable

     

     

    190

     

     

    (20)

    Inventories

     

     

    74

     

     

    63

    Other current assets

     

     

    41

     

     

    29

    Accounts payable and accrued expenses

     

     

    (290)

     

     

    (243)

    Net cash provided by operating activities

     

     

    197

     

     

    27

     

     

     

     

     

     

     

    Cash flows from investing activities:

     

     

     

     

     

     

    Purchases of property and equipment

     

     

    (41)

     

     

    (31)

    Payments related to equity investments and business acquisitions, net of cash acquired

     

     

    (20)

     

     

    (1)

    Proceeds from loan to affiliate

     

     

    1

     

     

    2

    Capitalized software costs

     

     

    (9)

     

     

    (9)

    Other

     

     

    (3)

     

     

    -

    Net cash used in investing activities

     

     

    (72)

     

     

    (39)

     

     

     

     

     

     

     

    Cash flows from financing activities:

     

     

     

     

     

     

    Net change in bank credit lines

     

     

    -

     

     

    132

    Proceeds from issuance of long-term debt

     

     

    90

     

     

    31

    Principal payments for long-term debt

     

     

    (60)

     

     

    (1)

    Proceeds from issuance of stock upon exercise of stock options

     

     

    1

     

     

    1

    Payments for repurchases and retirement of common stock

     

     

    (75)

     

     

    (100)

    Payments for taxes related to shares withheld for employee taxes

     

     

    (7)

     

     

    (30)

    Distributions to noncontrolling shareholders

     

     

    (6)

     

     

    (4)

    Acquisitions of noncontrolling interests in subsidiaries

     

     

    (94)

     

     

    (8)

    Net cash provided by (used in) financing activities

     

     

    (151)

     

     

    21

     

     

     

     

     

     

     

    Effect of exchange rate changes on cash and cash equivalents

     

     

    14

     

     

    -

     

     

     

     

     

     

     

    Net change in cash and cash equivalents

     

     

    (12)

     

     

    9

    Cash and cash equivalents, beginning of period

     

     

    171

     

     

    117

    Cash and cash equivalents, end of period

     

    $

    159

     

    $

    126

    Exhibit A - First Quarter Sales

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Henry Schein, Inc.

    2024 First Quarter

    Sales Summary

    (in millions)

    (unaudited)

    Q1 2024 over Q1 2023

     

     

     

     

     

     

     

     

    Local Currency Growth

     

     

     

     

     

     

    Global

    Q1 2024

     

    Q1 2023

     

    Local Internal Growth

     

    Acquisition Growth

     

    Total Local Currency Growth

     

    Foreign Exchange Impact

     

    Total Sales Growth

    Dental Merchandise

    $

    1,499

     

    $

    1,487

     

    -3.7%

     

    3.8%

     

    0.1%

     

    0.7%

     

    0.8%

    Dental Equipment

     

    415

     

     

    411

     

    0.2%

     

    0.0%

     

    0.2%

     

    0.6%

     

    0.8%

    Total Dental

     

    1,914

     

     

    1,898

     

    -2.9%

     

    3.0%

     

    0.1%

     

    0.7%

     

    0.8%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Medical

     

    1,041

     

     

    971

     

    -0.7%

     

    8.0%

     

    7.3%

     

    0.0%

     

    7.3%

    Total Health Care Distribution

     

    2,955

     

     

    2,869

     

    -2.1%

     

    4.6%

     

    2.5%

     

    0.5%

     

    3.0%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Technology and Value-Added Services

     

    217

     

     

    191

     

    3.2%

     

    10.2%

     

    13.4%

     

    0.4%

     

    13.8%

    Total Global

    $

    3,172

     

    $

    3,060

     

    -1.8%

     

    5.0%

     

    3.2%

     

    0.5%

     

    3.7%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Local Currency Growth

     

     

     

     

     

     

    North America

    Q1 2024

     

    Q1 2023

     

    Local Internal Growth

     

    Acquisition Growth

     

    Total Local Currency Growth

     

    Foreign Exchange Impact

     

    Total Sales Growth

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Dental Merchandise

    $

    848

     

    $

    896

     

    -5.5%

     

    0.1%

     

    -5.4%

     

    0.0%

     

    -5.4%

    Dental Equipment

     

    255

     

     

    248

     

    2.9%

     

    0.0%

     

    2.9%

     

    0.1%

     

    3.0%

    Total Dental

     

    1,103

     

     

    1,144

     

    -3.7%

     

    0.1%

     

    -3.6%

     

    0.0%

     

    -3.6%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Medical

     

    1,014

     

     

    951

     

    -0.5%

     

    7.1%

     

    6.6%

     

    0.0%

     

    6.6%

    Total Health Care Distribution

     

    2,117

     

     

    2,095

     

    -2.2%

     

    3.2%

     

    1.0%

     

    0.1%

     

    1.1%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Technology and Value-Added Services

     

    189

     

     

    166

     

    2.3%

     

    11.6%

     

    13.9%

     

    0.0%

     

    13.9%

    Total North America

    $

    2,306

     

    $

    2,261

     

    -1.9%

     

    3.9%

     

    2.0%

     

    0.0%

     

    2.0%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Local Currency Growth

     

     

     

     

     

     

    International

    Q1 2024

     

    Q1 2023

     

    Local Internal Growth

     

    Acquisition Growth

     

    Total Local Currency Growth

     

    Foreign Exchange Impact

     

    Total Sales Growth

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Dental Merchandise

    $

    651

     

    $

    591

     

    -1.0%

     

    9.4%

     

    8.4%

     

    1.8%

     

    10.2%

    Dental Equipment

     

    160

     

     

    163

     

    -3.8%

     

    0.0%

     

    -3.8%

     

    1.3%

     

    -2.5%

    Total Dental

     

    811

     

     

    754

     

    -1.6%

     

    7.4%

     

    5.8%

     

    1.6%

     

    7.4%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Medical

     

    27

     

     

    20

     

    -10.4%

     

    50.8%

     

    40.4%

     

    0.0%

     

    40.4%

    Total Health Care Distribution

     

    838

     

     

    774

     

    -1.8%

     

    8.5%

     

    6.7%

     

    1.6%

     

    8.3%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Technology and Value-Added Services

     

    28

     

     

    25

     

    8.9%

     

    0.6%

     

    9.5%

     

    3.2%

     

    12.7%

    Total International

    $

    866

     

    $

    799

     

    -1.5%

     

    8.2%

     

    6.7%

     

    1.7%

     

    8.4%

    Exhibit B

     

     

     

     

     

     

     

     

     

    Henry Schein, Inc.

    2024 First Quarter

    Reconciliation of reported GAAP net income and diluted EPS attributable to Henry Schein, Inc.

    to non-GAAP net income and diluted EPS attributable to Henry Schein, Inc.

    (in millions, except per share data)

    (unaudited)

     

     

     

    First Quarter

     

     

     

     

     

     

     

     

    %

     

     

     

    2024

     

     

    2023

     

    Growth

     

    Net income attributable to Henry Schein, Inc.

    $

    93

     

    $

    121

     

    (23.2)

    %

    Diluted EPS attributable to Henry Schein, Inc.

    $

    0.72

     

    $

    0.91

     

    (20.9)

    %

     

     

     

     

     

     

     

     

     

    Non-GAAP Adjustments, net of tax and attribution to noncontrolling interests

     

     

     

     

     

     

     

     

    Restructuring costs (1)

    $

    7

     

    $

    21

     

     

     

    Acquisition intangible amortization (2)

     

    28

     

     

    19

     

     

     

    Cyber incident-third-party advisory expenses (3)

     

    4

     

     

    -

     

     

     

    Change in contingent consideration (4)

     

    11

     

     

    -

     

     

     

    Non-GAAP adjustments to net income

    $

    50

     

    $

    40

     

     

     

     

     

     

     

     

     

     

     

     

    Non-GAAP adjustments to diluted EPS

    $

    0.38

     

    $

    0.30

     

     

     

     

     

     

     

     

     

     

     

     

    Non-GAAP net income attributable to Henry Schein, Inc.

    $

    143

     

    $

    161

     

    (11.3)

    %

    Non-GAAP diluted EPS attributable to Henry Schein, Inc.

    $

    1.10

     

    $

    1.21

     

    (9.1)

    %

    Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures. Net income growth rates are based on actual values and may not recalculate due to rounding. Amounts may not sum due to rounding.

    (1)

    Restructuring Costs

     

     

     

     

     

     

     

     

     

     

     

    The following table presents details of our restructuring costs:

     

     

     

    First Quarter

     

     

     

    2024

     

     

    2023

     

    Restructuring costs - pre-tax, as reported

    $

    10

     

    $

    30

     

    Income tax benefit

     

    (3)

     

     

    (8)

     

    Amount attributable to noncontrolling interests

     

    -

     

     

    (1)

     

    Restructuring costs, net

    $

    7

     

    $

    21

    Q1 2024 restructuring costs primarily consisted of employee severance and costs related to the exit of facilities.

    (2)

    Acquisition Intangible Amortization

     

     

     

     

     

     

     

     

     

     

     

     

    The following table presents details of amortization of acquired intangible assets:

     

     

     

    First Quarter

     

     

     

    2024

     

     

    2023

     

    Acquisition intangible amortization - pre-tax, as reported

    $

    46

     

    $

    30

     

    Income tax benefit

     

    (11)

     

     

    (7)

     

    Amount attributable to noncontrolling interests

     

    (7)

     

     

    (4)

     

    Acquisition intangible amortization, net

    $

    28

     

    $

    19

    (3)

    Represents one time professional and other fees of $5 million ($4 million, net of taxes) related to remediation of our Q4 2023 cyber incident.

    (4)

    Represents a change in the fair value of contingent consideration of $15 million ($11 million, net of taxes) recorded during Q1 2024 related to a 2023 acquisition.

    Exhibit C

     

     

     

     

     

     

     

    Henry Schein, Inc.

    2024 First Quarter

    Reconciliation of reported GAAP net income to Adjusted EBITDA

    (in millions)

    (unaudited)

     

     

     

     

     

     

     

     

     

    First Quarter

     

     

    2024

     

     

    2023

     

    Net income attributable to Henry Schein, Inc. (GAAP)

    $

    93

     

    $

    121

     

    Income attributable to noncontrolling interests

     

    5

     

     

    7

     

    Net income (GAAP)

     

    98

     

     

    128

     

    Definitional adjustments:

     

     

     

     

     

     

    Interest income

     

    (5)

     

     

    (3)

     

    Interest expense

     

    30

     

     

    14

     

    Income taxes

     

    32

     

     

    39

     

    Depreciation and amortization

     

    73

     

     

    52

     

    Non-GAAP adjustments:

     

     

     

     

     

     

    Restructuring costs

     

    10

     

     

    30

     

    Cyber incident-professional and other fees

     

    5

     

     

    -

     

    Change in contingent consideration

     

    15

     

     

    -

     

    Other adjustments:

     

     

     

     

     

     

    Equity in earnings of affiliates, net of tax

     

    (3)

     

     

    (4)

     

    Adjusted EBITDA (non-GAAP)

    $

    255

     

    $

    256

     

     

    Adjusted EBITDA is a non-GAAP measure that we calculate in the manner reflected on Exhibit C. We define Adjusted EBITDA as net income, excluding (i) net income attributable to noncontrolling interests, (ii) interest income and expense, (iii) income taxes, (iv) depreciation and amortization, (v) restructuring costs, (vi) cyber incident-professional and other fees, (vii) change in contingent consideration, and (viii) equity in earnings of affiliates. Amounts may not sum due to rounding.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240505165642/en/

    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    12/9/2025$86.00Overweight
    Barclays
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    7/25/2025$75.00Buy → Hold
    Stifel
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $HSIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein One Launches Image Verify, Another Transformative Step Towards Achieving the Cleanest Claims in the Industry

    New Native, AI-Embedded Capability in Dentrix and Dentrix Ascend Helps Improve Image Quality Control at Capture Henry Schein One, the market leader in dental practice management systems, today announced the launch of AI-driven Image Verify, the latest innovation in a rapid series of product advancements designed to deliver the cleanest claims experience in dentistry. Image Verify, natively embedded in Dentrix and Dentrix Ascend, represents another major step towards the company's bold Clean Claims vision – a future where dental practices submit claims once and never have to touch them again. As the market leader in dental cloud-based technology, Henry Schein One has accelerated developm

    2/19/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein One Connects Align Technology's iTero™ Scanners to Dentrix, Dentrix Ascend, and Dentally, Advancing a More Connected Global Standard of Care

    New integration unifies diagnosis, treatment planning, and practice management Henry Schein One today announced a direct data integration between Align Technology's iTero™ intraoral scanners and its core practice management platforms—Dentrix, Dentrix Ascend, and Dentally—creating a seamless connection between digital scanning, diagnosis, and daily operations for practices worldwide. Developed in collaboration with Align Technology, the integration automatically imports iTero scans into patient records, eliminating manual uploads, duplicate workflows, and system switching. This integration with iTero scanners enables teams to move efficiently from scan to care within a single, connected

    2/17/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry S

    1/22/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    SEC Filings

    View All

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    1/12/26 7:00:12 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    12/23/25 4:05:30 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    12/23/25 7:00:20 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Henry Schein with a new price target

    Barclays initiated coverage of Henry Schein with a rating of Overweight and set a new price target of $86.00

    12/9/25 8:50:15 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Henry Schein from In-line to Outperform and set a new price target of $83.00

    8/26/25 8:13:41 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein downgraded by Stifel with a new price target

    Stifel downgraded Henry Schein from Buy to Hold and set a new price target of $75.00

    7/25/25 8:58:32 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, Global Dist. & Tech. Albertini Andrea covered exercise/tax liability with 2,032 shares, decreasing direct ownership by 3% to 65,900 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    12/11/25 4:14:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 4 filed by Large owner Kkr Hawaii Aggregator L.P.

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    12/9/25 9:05:50 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Chairman, CEO Bergman Stanley M gifted 140 units of Common Stock par value $0.01 per shre and gifted 500 shares, decreasing direct ownership by 0.20% to 319,877 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    11/26/25 4:10:29 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Financials

    Live finance-specific insights

    View All

    Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry S

    1/22/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Record Third Quarter 2025 Financial Results and Raises Full Year Non-GAAP EPS Guidance

    Q3 2025 GAAP diluted EPS of $0.84, compared to $0.78 GAAP diluted EPS in Q3 2024, and Q3 2025 non-GAAP diluted EPS of $1.38, compared to $1.22 non-GAAP diluted EPS in Q3 2024 Raises 2025 guidance for non-GAAP diluted EPS to $4.88 to $4.96 and sales growth to 3-4% to reflect third quarter results Announces value creation initiatives expected to deliver over $200 million of operating income improvement over the next few years Agreement reached to provide KKR the right to increase its HSIC stock ownership up to 19.9% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results

    11/4/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast Third Quarter 2025 Conference Call on Tuesday, November 4, 2025, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its third quarter 2025 financial results before the stock market opens on Tuesday, November 4, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry Sc

    10/21/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care